NABLA BIO
Nabla is an autoreverse platform that enables the rapid discovery of previously unattainable protein variants with supernatural qualities. Nabla Bio makes new medicines and improve nutrition by engineering novel proteins.
NABLA BIO
Industry:
Biopharma Biotechnology Machine Learning
Founded:
2020-05-29
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.nabla.bio
Total Employee:
1+
Status:
Active
Total Funding:
11.26 M USD
Technology used in webpage:
Google Apps For Business Squarespace Hosted
Similar Organizations
Engine Biosciences
Engine Biosciences is a biotech company that applies machine learning to genomics for drug discovery.
Menten AI
Menten AI develops peptide and protein therapeutics using machine learning and quantum computing.
Metagenomi
Metagenomi is using the power of metagenomics and machine learning to discover novel genome editing systems.
Current Employees Featured
Frances Anastassacos Co-Founder @ Nabla Bio
Co-Founder
2020-06-01
Surge Biswas Co-Founder and CEO @ Nabla Bio
Co-Founder and CEO
2020-04-01
Founder
Investors List
Zetta Venture Partners
Zetta Venture Partners investment in Seed Round - Nabla Bio
Cantos
Cantos investment in Seed Round - Nabla Bio
Fifty Years
Fifty Years investment in Seed Round - Nabla Bio
Khosla Ventures
Khosla Ventures investment in Seed Round - Nabla Bio
Y Combinator
Y Combinator investment in Pre Seed Round - Nabla Bio
Fifty Years
Fifty Years investment in Pre Seed Round - Nabla Bio
National Science Foundation
National Science Foundation investment in Grant - Nabla Bio
Official Site Inspections
http://www.nabla.bio Semrush global rank: 4.86 M Semrush visits lastest month: 1.82 K
- Host name: 76.76.21.21
- IP address: 76.76.21.21
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
Cannot get whois informations of this domain!!!
More informations about "Nabla Bio"
Nabla
Founded by pioneers of protein language modeling, Nabla develops generative models, multiplexed screens, and protein characterization technologies and applies them to design …See details»
Nabla
Our founders developed the first protein language models in George Church's Lab and founded the company to combine generative models with massively multiplex experiments to design protein based therapies for applications …See details»
Nabla Bio - Crunchbase Company Profile & Funding
Nabla Bio is an autoverse platform of proprietary biologically informed machine learning that co-develops antibody drugs. Nabla Bio secured $26 million in Series A funding and announced collaborations with AstraZeneca, Bristol Myers …See details»
Nabla Bio Company Profile 2024: Valuation, Funding
Developer of autoverse platform designed for medical and industrial applications.See details»
Generative drug design meets massively parallel …
We're developing an integrated AI and wet-lab platform to enable precise drug design and high-throughput measurement of drug properties. Our initial focus is on designing biologics targeting multipass membrane proteins, such as G …See details»
Nabla Bio - Funding, Financials, Valuation & Investors - Crunchbase
Nabla Bio is an autoverse platform of proprietary biologically informed machine learning that co-develops antibody drugs.See details»
Nabla Bio Secures $26M Series A Financing and Collaborations …
May 14, 2024 · Company builds integrated AI and wet lab technologies to design developable, selective, and functionally active protein drugs against multipass membrane protein targets. …See details»
Nabla Bio - VentureRadar
Website: https://www.nabla.bio/ Develops integrated AI and wet-lab technologies for precise drug design and measurement, specializing in antibodies targeting multipass membrane proteins, …See details»
Nabla Bio Secures $26 Million Funding Boost to Drive …
May 15, 2024 · Nabla Bio, known for its groundbreaking work in generative protein design, has unveiled the successful closure of a $26 million Series A financing round.See details»
Nabla Bio secures $26m in Series A funding round
May 15, 2024 · US pharmaceutical company Nabla Bio has secured $26m for generative protein design in a Series A financing round led by Radical Ventures. The round included full participation from all existing investors. Nabla has also …See details»
Nabla Bio Secures $26M in Series A Funding Round
Nabla Bio announces a $26M Series A raise and strategic collaborations with major pharma, advancing generative protein design technology.See details»
Nabla · Enjoy care again
Nabla has been recognized in the KLAS Emerging Company Spotlight Report as the most customizable and intuitive ambient AI assistant. The leading ambient AI assistant, freeing …See details»
Nabla Bio Secures $26M Series A Financing and Collaborations …
Nabla develops integrated AI and wet-lab technologies that enable atomically precise drug design and high-throughput measurement of drug function, with an initial focus on antibodies targeting …See details»
Nabla Bio Advances Generative Protein Design with $26M
May 15, 2024 · Nabla Bio, a biotechnology firm specializing in generative protein design, has successfully closed a $26 million Series A financing round, led by Radical Ventures. The …See details»
Nabla Bio Secures $26M Series A Financing and Collaborations …
May 15, 2024 · Nabla Bio, pioneers in generative protein design, announced the close of a $26 million Series A financing, led by Radical Ventures with participation from all existing investors, …See details»
Nabla
6 days ago · Today, we’re thrilled to share a major advance in our ability to design antibodies fully computationally. We developed a new AI protein design system, JAM, capable of designing …See details»
Nabla Bio Closes $11M Seed Financing led by Khosla Ventures and …
Dec 6, 2021 · BOSTON-- (BUSINESS WIRE)--Nabla Bio, a next-generation antibody design company, announced the closing of a $11M Seed financing round. The round was co-led by …See details»
Designing Antibodies. Why we invested in Nabla Bio - Medium
Dec 6, 2021 · Essentially, Nabla’s Autoverse can design proteins from scratch with minimal prior knowledge — solving the decades long biotech question of how do proteins go from sequence …See details»
Global Press Release & Newswire Distribution Services | Business …
Nabla Bio secures series A financing and collaborations with AstraZeneca, Bristol-Myers Squibb, and Takeda for generative protein design.See details»